Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)

NCT01934647 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: MK-8892

Sponsor

Merck Sharp & Dohme LLC